Trials / Not Yet Recruiting
Not Yet RecruitingNCT06565871
A Study of HRS9531 Injection in Obese Subjects With Obstructive Sleep Apnea
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Phase II Study to Evaluate the Efficacy and Safety of HRS9531 Injection in Obese Subjects With Obstructive Sleep Apnea (OSA)
- Status
- Not Yet Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 108 (estimated)
- Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the effect and safety of HRS9531 Injection in Obese Subjects with Obstructive Sleep Apnea
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HRS9531 Injection | Titration administration, SC |
| DRUG | HRS9531 Injection | Titration administration, SC |
| DRUG | Placebo Injection | SC |
Timeline
- Start date
- 2024-08-01
- Primary completion
- 2025-12-01
- Completion
- 2025-12-01
- First posted
- 2024-08-22
- Last updated
- 2024-08-22
Source: ClinicalTrials.gov record NCT06565871. Inclusion in this directory is not an endorsement.